+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
BLISSGVS

Bliss GVS Pharma Share Price

₹579.10 -1.05 (-0.18%)
New 52W High in past week

21 Aug, 2026 3:51 PM (IST)

Bliss GVS Pharma live price: ₹579.10. It opened at ₹582 vs previous close ₹580; intraday high/low: ₹593/₹560. The 50 & 200 DMA stand at ₹478.30/₹333.20.

Bliss GVS Pharma Performance

  • Today's Low
  • ₹560
  • Today's High
  • ₹593
  • 52 Week Low
  • ₹118
  • 52 Week High
  • ₹602
  • Open Price₹582
  • Previous Close₹580
  • Volume222,726
  • 50 DMA₹478.30
  • 100 DMA₹415.30
  • 200 DMA₹333.20

Bliss GVS Pharma Chart

Investment Returns

  • Over 1 Month + 25.39%
  • Over 3 Month + 92.81%
  • Over 6 Month + 157.3%
  • Over 1 Year + 259.02%

Smart Investing Starts Here Start SIP with Bliss GVS Pharma for Steady Growth!

Invest Now

Bliss GVS Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 45.2
  • PEG Ratio
  • 1.6
  • Market Cap Cr
  • 6,154
  • P/B Ratio
  • 4.9
  • Average True Range
  • 27.2
  • EPS
  • 12.8
  • Dividend Yield
  • 0.3
  • MACD Signal
  • 24.3
  • RSI
  • 75.87
  • MFI
  • 84.17

Latest Stock News Updates

Bliss GVS Pharma Ltd - 506197 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Please find enclosed herewith the Newspaper Publication regarding the publication of the advertisement for the Postal Ballot Notice.

Bliss GVS Pharma Ltd - 506197 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

Please find enclosed herewith the Postal Ballot Notice ("Notice") dated August 12, 2026, alongwith the Explanatory Statement for seeking approval of Members of the Company by way of remote e-voting process to transact the business as set out in the Notice.

Bliss GVS Pharma Ltd - 506197 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Please find enclosed herewith the copies of newspaper advertisement published regarding the extract of statement of Un-audited Standalone and Consolidated Financial Results of the Company for the Quarter ended June 30, 2026.

Bliss GVS Pharma Financials

Bliss GVS Pharma Technicals

EMA & SMA

Current Price
₹579.10
-1.05 (-0.18%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹517.00
  • 50 Day
  • ₹478.30
  • 100 Day
  • ₹415.30
  • 200 Day
  • ₹333.20

Resistance and Support

577.37 Pivot Speed
  • R3 627.70
  • R2 610.40
  • R1 594.70
  • S1 561.70
  • S2 544.40
  • S3 528.70

Bliss GVS Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-12 Quarterly Results
2026-05-12 Audited Results & Final Dividend
2026-02-10 Quarterly Results & Interim Dividend
2025-11-06 Quarterly Results
2025-07-29 Quarterly Results
Date Purpose Remarks
2026-07-08 FINAL Rs.1.00 per share(100%)Final Dividend
2026-02-18 INTERIM Rs.0.50 per share(50%)Interim Dividend
2025-07-24 FINAL Rs.0.50 per share(50%)Final Dividend
View Bliss GVS Pharma Dividend History Arrow
Date Purpose Remarks
2008-03-18 Split Stock Split from Rs. 10/- to Re. 1/-.

Bliss GVS Pharma Shareholding Pattern

47.45%
35.01%
9.2%
8.07%
0.26%

About Bliss GVS Pharma

Bliss GVS Pharma is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company is one of among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. View More
  • NSE Symbol
  • BLISSGVS
  • BSE Symbol
  • 506197
  • ISIN
  • INE416D01022

Similar Stocks to Bliss GVS Pharma

Bliss GVS Pharma FAQs

Bliss GVS Pharma share price is ₹579 As on 24 August, 2026 | 08:02

The Market Cap of Bliss GVS Pharma is ₹6154.4 Cr As on 24 August, 2026 | 08:02

The P/E ratio of Bliss GVS Pharma is 45.2 As on 24 August, 2026 | 08:02

The PB ratio of Bliss GVS Pharma is 4.9 As on 24 August, 2026 | 08:02

The 52 week High & Low of Bliss GVS Pharma is ₹602.4/₹118 respectively As on 24 August, 2026 | 08:02

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23